Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

72.47USD
12:03pm EDT
Change (% chg)

$0.26 (+0.36%)
Prev Close
$72.21
Open
$72.20
Day's High
$72.65
Day's Low
$71.94
Volume
1,354,127
Avg. Vol
2,697,664
52-wk High
$72.89
52-wk Low
$52.83

Select another date:

Thu, Oct 18 2018

Photo

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Oct 18 Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.

UPDATE 1-Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK, Oct 2 The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK, Oct 2 Craig Thompson, chief executive of Memorial Sloan Kettering Cancer Center, resigned from the board of drugmaker Merck & Co Inc on Tuesday, after questions about the cancer center's ties to the pharmaceutical industry.

Merck's Frazier to remain CEO of the U.S. drugmaker beyond 2019

Merck & Co Inc Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEOs to retire at the age of 65.

UPDATE 5-Merck's Frazier to remain CEO of the U.S. drugmaker beyond 2019

Sept 26 Merck & Co Inc Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEOs to retire at the age of 65.

Merck CEO to stay post 65 after company amends retirement policy

Sept 26 Drugmaker Merck and Co Inc said on Wednesday that its board voted to rescind a policy requiring its head to retire at 65, a move that will permit current Chief Executive Officer Kenneth Frazier to remain in the role beyond next year.

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON, Sept 10 Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

Select another date: